RTX Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RTX Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $80.74B | Feb 3, 2025 |
| FY2024 | Dec 31, 2023 | $68.92B | Feb 3, 2025 |
| FY2024 | Dec 31, 2022 | $67.07B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $64.39B | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | $16.42B | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $14.75B | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $14.06B | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $11.36B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $11.69B | Feb 8, 2021 |
| FY2020 | Sep 30, 2019 | $11.37B | Feb 8, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.60B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $80.74B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $68.92B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $67.07B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $64.39B | Feb 5, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $15.68B | Feb 9, 2018 |
| FY2017 | Sep 30, 2017 | $15.06B | Feb 9, 2018 |
| FY2017 | Jun 30, 2017 | $15.28B | Feb 9, 2018 |
| FY2017 | Mar 31, 2017 | $13.82B | Feb 9, 2018 |
| FY2017 | Dec 31, 2016 | $14.66B | Feb 9, 2018 |
| FY2017 | Sep 30, 2016 | $14.35B | Feb 9, 2018 |
| FY2017 | Jun 30, 2016 | $14.87B | Feb 9, 2018 |
| FY2017 | Mar 31, 2016 | $13.36B | Feb 9, 2018 |
| FY2016 | Dec 31, 2015 | $14.30B | Feb 9, 2017 |
| FY2016 | Sep 30, 2015 | $13.79B | Feb 9, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.15B | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $1.74B | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $1.85B | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $2.79B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $2.58B | Feb 8, 2021 |
| FY2020 | Sep 30, 2019 | $2.86B | Feb 8, 2021 |
| FY2020 | Jun 30, 2019 | $2.78B | Feb 8, 2021 |
| FY2020 | Mar 31, 2019 | $2.53B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $4.30B | Feb 6, 2020 |
| FY2019 | Sep 30, 2018 | $3.97B | Feb 6, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.73B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $4.77B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $3.20B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $5.20B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $3.86B | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | $135.00M | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $264.00M | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | ($3.84B) | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | ($83.00M) | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $1.14B | Feb 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.30B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $6.54B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $3.56B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $5.50B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $5.14B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | ($1.89B) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $4.91B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.88B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $8.14B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $8.22B | Feb 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.81B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.93B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $2.81B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $2.71B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $2.73B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $2.58B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $2.45B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $1.88B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.43B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $2.38B | Feb 7, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.10B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.81B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $5.81B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $5.57B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $5.05B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $5.54B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $3.71B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.86B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $6.43B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $5.96B | Feb 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.57B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $7.16B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $7.88B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $7.17B | Feb 3, 2025 |
| FY2014 | Dec 31, 2014 | $7.34B | Feb 5, 2015 |
| FY2014 | Dec 31, 2013 | $7.51B | Feb 5, 2015 |
| FY2014 | Dec 31, 2012 | $6.61B | Feb 5, 2015 |
| FY2013 | Dec 31, 2011 | $6.46B | Feb 6, 2014 |
| FY2012 | Dec 31, 2010 | $5.72B | Feb 7, 2013 |
| FY2011 | Dec 31, 2009 | $5.35B | Feb 9, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.63B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.63B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $2.42B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $2.29B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $2.13B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $1.80B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $1.87B | Feb 11, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $171.08B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $162.86B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $161.87B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $158.86B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $161.40B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $162.15B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $139.62B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $134.21B | Feb 6, 2020 |
| FY2019 | Dec 31, 2017 | $96.92B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $89.71B | Feb 7, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.94B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $100.90B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $100.42B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $84.65B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $86.71B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $88.27B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $95.29B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $93.49B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $65.37B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $60.24B | Feb 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.25B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $60.16B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $59.80B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $72.63B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $73.07B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $72.16B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $41.77B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $38.45B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $29.61B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $27.58B | Feb 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.34B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $52.79B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $53.70B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $53.84B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $54.44B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $54.29B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $36.61B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $48.11B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $27.91B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $27.06B | Feb 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.72B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $53.59B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $52.15B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $52.27B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $50.27B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $49.42B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $61.59B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $57.82B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $55.24B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $52.87B | Feb 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.44B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.58B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $6.59B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $6.22B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $7.83B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $8.80B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $4.94B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $3.69B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $8.99B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $7.16B | Feb 7, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $41.08B | Feb 3, 2025 |
| FY2024 | Dec 31, 2023 | $43.64B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $31.29B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $31.35B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $31.58B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $40.96B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $44.07B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $27.09B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $23.30B | Feb 9, 2018 |
| FY2016 | Dec 31, 2015 | $19.50B | Feb 9, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | (2) | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 8, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | (2) | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 8, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2009 | Dec 31, 2009 | 1.38M | Feb 11, 2010 |
| FY2009 | Dec 31, 2008 | 1.37M | Feb 11, 2010 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.57B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.22B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $3.24B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $3.13B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $2.96B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $2.73B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $2.44B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.17B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.07B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $2.07B | Feb 7, 2019 |